Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ immunology
Blood Cell Count
CD4-Positive T-Lymphocytes
/ cytology
Female
Flow Cytometry
Humans
Immune Checkpoint Inhibitors
/ therapeutic use
Immunity, Cellular
Immunotherapy, Adoptive
Lymphocyte Count
Male
Melanoma
/ blood
Middle Aged
Monocytes
/ cytology
Myeloid-Derived Suppressor Cells
/ cytology
Platelet Count
Receptors, Chimeric Antigen
Skin Neoplasms
/ blood
Survival Analysis
T-Lymphocytes, Regulatory
/ cytology
Melanoma, Cutaneous Malignant
checkpoint inhibitor
immunotherapy
malignant melanoma
myeloid-derived suppressor cells
platelets
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
05
10
2020
revised:
25
11
2020
accepted:
18
12
2020
pubmed:
16
1
2021
medline:
17
7
2021
entrez:
15
1
2021
Statut:
ppublish
Résumé
Malignant melanoma is an immunogenic skin cancer with an increasing global incidence. Advanced stages of melanoma have poor prognoses. Currently, there are no reliable parameters to predict a patient's response to immune checkpoint inhibitor (ICI) therapy. This study highlights the relevance of a distinct immune signature in the blood for response to ICI therapy and overall survival (OS). Therefore, the immune cell composition in the peripheral blood of 45 melanoma patients prior to ICI therapy was analyzed by flow cytometry and complete blood count. Responders to ICI therapy displayed an abundance of proliferating CD4 Our study demonstrated that the observed immune signature in the peripheral blood of melanoma patients prior to treatment could identify responders as well as non-responders that benefit from ICI immunotherapies.
Sections du résumé
BACKGROUND
Malignant melanoma is an immunogenic skin cancer with an increasing global incidence. Advanced stages of melanoma have poor prognoses. Currently, there are no reliable parameters to predict a patient's response to immune checkpoint inhibitor (ICI) therapy.
METHODS
This study highlights the relevance of a distinct immune signature in the blood for response to ICI therapy and overall survival (OS). Therefore, the immune cell composition in the peripheral blood of 45 melanoma patients prior to ICI therapy was analyzed by flow cytometry and complete blood count.
RESULTS
Responders to ICI therapy displayed an abundance of proliferating CD4
CONCLUSIONS
Our study demonstrated that the observed immune signature in the peripheral blood of melanoma patients prior to treatment could identify responders as well as non-responders that benefit from ICI immunotherapies.
Identifiants
pubmed: 33449393
doi: 10.1002/cam4.3710
pmc: PMC7940230
doi:
Substances chimiques
Biomarkers, Tumor
0
Immune Checkpoint Inhibitors
0
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1562-1575Informations de copyright
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Clin Cancer Res. 2020 May 1;26(9):2257-2267
pubmed: 31932494
Cell Biosci. 2018 Apr 18;8:30
pubmed: 29713453
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Curr Opin Chem Eng. 2018 Mar;19:9-20
pubmed: 29623254
Br J Cancer. 2010 Jun 8;102(12):1724-30
pubmed: 20531415
PLoS Biol. 2011 Oct;9(10):e1001171
pubmed: 22022231
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
P T. 2016 Mar;41(3):185-91
pubmed: 26957887
Science. 2011 Apr 29;332(6029):600-3
pubmed: 21474713
Cancer Immunol Immunother. 2014 Mar;63(3):247-57
pubmed: 24357148
Sci Rep. 2017 Jun 7;7(1):2970
pubmed: 28592835
Cancer Gene Ther. 2021 Feb;28(1-2):5-17
pubmed: 32457487
Front Immunol. 2019 Jun 18;10:1336
pubmed: 31275310
Cancer Immunol Immunother. 2013 Nov;62(11):1711-22
pubmed: 24072401
Nat Rev Cancer. 2015 Feb;15(2):96-109
pubmed: 25614008
Science. 2015 Oct 9;350(6257):207-211
pubmed: 26359337
Cells. 2020 Feb 27;9(3):
pubmed: 32121014
Cell. 2018 Nov 1;175(4):998-1013.e20
pubmed: 30388456
J Immunol Methods. 2010 Oct 31;362(1-2):43-50
pubmed: 20800066
Front Immunol. 2017 Sep 29;8:1215
pubmed: 29033936
Clin Cancer Res. 2016 Nov 15;22(22):5487-5496
pubmed: 27185375
Cancer. 2017 Jun 1;123(S11):2130-2142
pubmed: 28543700
Cell Immunol. 2019 Sep;343:103713
pubmed: 29129292
Cancer Immunol Immunother. 2016 Feb;65(2):161-9
pubmed: 26728481
Nat Med. 2019 Dec;25(12):1916-1927
pubmed: 31792460
J Immunol Methods. 2012 Jul 31;381(1-2):14-22
pubmed: 22522114
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
pubmed: 16344461
J Immunol. 2006 Apr 15;176(8):4622-31
pubmed: 16585553
Transpl Int. 2013 Mar;26(3):290-9
pubmed: 23279010
Front Oncol. 2018 Mar 22;8:80
pubmed: 29623257
Front Immunol. 2018 Jun 11;9:1310
pubmed: 29942309
Exp Dermatol. 2014 Mar;23(3):202-4
pubmed: 24495013
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
Blood. 2013 Aug 15;122(7):1182-91
pubmed: 23818544
ESMO Open. 2017 Jul 3;2(2):e000213
pubmed: 28761757
Curr Protoc Cytom. 2010 Jul;Chapter 10:Unit10.17
pubmed: 20578106
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Clin Ther. 2019 Jan;41(1):59-67
pubmed: 30528047
J Exp Med. 2013 Aug 26;210(9):1695-710
pubmed: 23897981
Cancer Res. 2015 Jan 15;75(2):275-83
pubmed: 25406192
Front Oncol. 2018 Jul 18;8:270
pubmed: 30073150
Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13445-50
pubmed: 19651619
Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20410-5
pubmed: 19074257